About this Research Topic
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related death among female patients, which seriously threatens the health of women globally. Despite significant progress in breast cancer treatment, resistance to chemotherapeutic agents remains a major barrier to effective therapy. Various factors and molecular mechanisms contribute to chemoresistance, including alterations in drug targets, apoptotic dysregulation, overexpression of ABC transporters, epithelial-to-mesenchymal transitions, cancer stem cells, epigenetic modifications, etc. These underlying mechanisms are complicated and need further investigation. A better understanding of the drug resistance mechanisms can enhance therapeutic efficacy and outcomes.
We are currently witnessing a new era in cancer therapeutics marked by an increasing number of treatment options for breast cancer. The development of agents with improved specificity and the establishment of an optimized therapeutic approach hold promise for better management and survival outcomes for breast cancer patients. In this Research topic, we aim to delve into the identification of new targets, biomarkers, and underlying mechanisms associated with chemotherapy resistance in breast cancer. The primary objective is to explore novel therapeutic drugs and strategies that can enhance the efficacy of breast cancer chemotherapy. By addressing these critical areas, the research seeks to answer pivotal questions regarding the mechanisms of resistance and the potential for improved treatment outcomes. We invite contributors to address, but not limited to the following specific themes:
● Exploration and verification of predictive and/or prognostic biomarkers to address chemotherapy decisions or to overcome challenges and limitations of current breast cancer chemotherapy.
● New targets associated with chemotherapy resistance mechanism: intracellular drug concentrations decrease, DNA damage repair, cell death inhibition, cancer stem cell, the epithelial-mesenchymal transition (EMT), and epigenetic modifications.
● Translational research in screening and evaluating cytokines, antibodies, small molecules, or natural products alone or combined with chemotherapy drugs to improve treatment efficacy.
● Developing novel drug delivery systems (such as nanoparticles) to improve the therapeutic effectiveness and safety profile of traditional chemotherapeutic agents.
● Prospective or retrospective clinical trial data, real-world evidence, and comparative studies of breast cancer chemotherapy or combined with target therapy and immunotherapy.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
We are currently witnessing a new era in cancer therapeutics marked by an increasing number of treatment options for breast cancer. The development of agents with improved specificity and the establishment of an optimized therapeutic approach hold promise for better management and survival outcomes for breast cancer patients. In this Research topic, we aim to delve into the identification of new targets, biomarkers, and underlying mechanisms associated with chemotherapy resistance in breast cancer. The primary objective is to explore novel therapeutic drugs and strategies that can enhance the efficacy of breast cancer chemotherapy. By addressing these critical areas, the research seeks to answer pivotal questions regarding the mechanisms of resistance and the potential for improved treatment outcomes. We invite contributors to address, but not limited to the following specific themes:
● Exploration and verification of predictive and/or prognostic biomarkers to address chemotherapy decisions or to overcome challenges and limitations of current breast cancer chemotherapy.
● New targets associated with chemotherapy resistance mechanism: intracellular drug concentrations decrease, DNA damage repair, cell death inhibition, cancer stem cell, the epithelial-mesenchymal transition (EMT), and epigenetic modifications.
● Translational research in screening and evaluating cytokines, antibodies, small molecules, or natural products alone or combined with chemotherapy drugs to improve treatment efficacy.
● Developing novel drug delivery systems (such as nanoparticles) to improve the therapeutic effectiveness and safety profile of traditional chemotherapeutic agents.
● Prospective or retrospective clinical trial data, real-world evidence, and comparative studies of breast cancer chemotherapy or combined with target therapy and immunotherapy.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords: Breast Cancer, Chemotherapy, Biomarkers, Resistance, Nanoparticles
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
